Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma

Paolo A Ascierto, Lars Bastholt, Peter Hersey, Gabriela Cinat, Alexander M Eggermont, Axel Hauschild, Enrique Espinosa, Caroline Robert

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

As the incidence of melanoma continues to increase worldwide, the search for new therapies for advanced (stage IV) melanoma brings with it new patterns of toxicity to contend with. This review covers the toxicity profiles of new treatments for advanced melanoma currently in development. Therefore, the latest literature on melanoma treatment was surveyed for data on reported toxicities. The new types of treatments can be roughly divided into targeted tyrosine kinase inhibitors and immunomodulating agents. Each has its own set of toxicities particular to type and to individual drug. Targeted tyrosine kinase inhibitors generally cause fatigue, whereas immunomodulatory agents induce a specific set of adverse events known as immune-related adverse events (irAEs). Despite the incidence of adverse events, these agents hold promise for the treatment of stage IV melanoma. With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents.
OriginalsprogEngelsk
TidsskriftAmerican Journal of Therapeutics
ISSN1075-2765
DOI
StatusUdgivet - 31. okt. 2013

Fingeraftryk

Melanoma
Poisons
Incidence
Pharmaceutical Preparations

Citer dette

Ascierto, Paolo A ; Bastholt, Lars ; Hersey, Peter ; Cinat, Gabriela ; Eggermont, Alexander M ; Hauschild, Axel ; Espinosa, Enrique ; Robert, Caroline. / Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. I: American Journal of Therapeutics. 2013.
@article{183a63b26f7a453bae22af6b3a7f8abe,
title = "Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma",
abstract = "As the incidence of melanoma continues to increase worldwide, the search for new therapies for advanced (stage IV) melanoma brings with it new patterns of toxicity to contend with. This review covers the toxicity profiles of new treatments for advanced melanoma currently in development. Therefore, the latest literature on melanoma treatment was surveyed for data on reported toxicities. The new types of treatments can be roughly divided into targeted tyrosine kinase inhibitors and immunomodulating agents. Each has its own set of toxicities particular to type and to individual drug. Targeted tyrosine kinase inhibitors generally cause fatigue, whereas immunomodulatory agents induce a specific set of adverse events known as immune-related adverse events (irAEs). Despite the incidence of adverse events, these agents hold promise for the treatment of stage IV melanoma. With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents.",
author = "Ascierto, {Paolo A} and Lars Bastholt and Peter Hersey and Gabriela Cinat and Eggermont, {Alexander M} and Axel Hauschild and Enrique Espinosa and Caroline Robert",
year = "2013",
month = "10",
day = "31",
doi = "10.1097/MJT.0b013e3182a39858",
language = "English",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams & Wilkins",

}

Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. / Ascierto, Paolo A; Bastholt, Lars; Hersey, Peter; Cinat, Gabriela; Eggermont, Alexander M; Hauschild, Axel; Espinosa, Enrique; Robert, Caroline.

I: American Journal of Therapeutics, 31.10.2013.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma

AU - Ascierto, Paolo A

AU - Bastholt, Lars

AU - Hersey, Peter

AU - Cinat, Gabriela

AU - Eggermont, Alexander M

AU - Hauschild, Axel

AU - Espinosa, Enrique

AU - Robert, Caroline

PY - 2013/10/31

Y1 - 2013/10/31

N2 - As the incidence of melanoma continues to increase worldwide, the search for new therapies for advanced (stage IV) melanoma brings with it new patterns of toxicity to contend with. This review covers the toxicity profiles of new treatments for advanced melanoma currently in development. Therefore, the latest literature on melanoma treatment was surveyed for data on reported toxicities. The new types of treatments can be roughly divided into targeted tyrosine kinase inhibitors and immunomodulating agents. Each has its own set of toxicities particular to type and to individual drug. Targeted tyrosine kinase inhibitors generally cause fatigue, whereas immunomodulatory agents induce a specific set of adverse events known as immune-related adverse events (irAEs). Despite the incidence of adverse events, these agents hold promise for the treatment of stage IV melanoma. With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents.

AB - As the incidence of melanoma continues to increase worldwide, the search for new therapies for advanced (stage IV) melanoma brings with it new patterns of toxicity to contend with. This review covers the toxicity profiles of new treatments for advanced melanoma currently in development. Therefore, the latest literature on melanoma treatment was surveyed for data on reported toxicities. The new types of treatments can be roughly divided into targeted tyrosine kinase inhibitors and immunomodulating agents. Each has its own set of toxicities particular to type and to individual drug. Targeted tyrosine kinase inhibitors generally cause fatigue, whereas immunomodulatory agents induce a specific set of adverse events known as immune-related adverse events (irAEs). Despite the incidence of adverse events, these agents hold promise for the treatment of stage IV melanoma. With new treatment opportunities come increased chance of toxic reactions. The key to successful melanoma treatment in the future is likely to be novel combinations of new therapeutic agents.

U2 - 10.1097/MJT.0b013e3182a39858

DO - 10.1097/MJT.0b013e3182a39858

M3 - Journal article

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

ER -